BIOMERICA INC Selling and Marketing Expense
BIOMERICA INC (BMRA) reported Selling and Marketing Expense of $1.67 million for the 12-month period ending 2026-05-31, per its 10-K filed 2026-08-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingAndMarketingExpense · last filed 2026-08-31
- BIOMERICA INC selling and marketing expense for the quarter ending 2026-05-31 was $381.00K, a 1.33% increase year-over-year.
- BIOMERICA INC selling and marketing expense for the quarter ending 2026-02-28 was $415.00K, a 27.30% increase year-over-year.
- BIOMERICA INC selling and marketing expense for the quarter ending 2025-11-30 was $462.00K, a 6.45% increase year-over-year.
- BIOMERICA INC selling and marketing expense for the quarter ending 2025-08-31 was $1.33M, a 2.21% decline year-over-year.
- BIOMERICA INC selling and marketing expense for fiscal 2026 was $1.67M, a 2.27% increase from fiscal 2025.
- BIOMERICA INC selling and marketing expense for fiscal 2025 was $1.63M, a 30.40% decline from fiscal 2024.
- BIOMERICA INC selling and marketing expense for fiscal 2024 was $2.34M.
| Period end | Selling and Marketing Expense 3 month | Selling and Marketing Expense 6 month | Selling and Marketing Expense 9 month | Selling and Marketing Expense 12 month |
|---|---|---|---|---|
| 2026-05-31 | $381.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-31 | $796.00K derived: sum of 2 quarters · filed 2026-08-31 | $1.26M derived: sum of 3 quarters · filed 2026-08-31 | $1.67M 10-K · filed 2026-08-31 |
| 2026-02-28 | $415.00K 10-Q · filed 2026-04-13 | $877.00K derived: sum of 2 quarters · filed 2026-04-13 | $1.28M 10-Q · filed 2026-04-13 | $2.58M derived: sum of 4 quarters · filed 2026-08-31 |
| 2025-11-30 | $462.00K 10-Q · filed 2026-01-14 | $869.00K 10-Q · filed 2026-01-14 | $2.17M derived: sum of 3 quarters · filed 2026-08-31 | $2.49M derived: sum of 4 quarters · filed 2026-08-31 |
| 2025-08-31 | $1.33M 10-Q · filed 2025-10-14 | $1.71M derived: sum of 2 quarters · filed 2026-08-31 | $2.03M derived: sum of 3 quarters · filed 2026-08-31 | $2.47M derived: sum of 4 quarters · filed 2026-08-31 |
| 2025-05-31 | $376.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-08-31 | $702.00K derived: sum of 2 quarters · filed 2026-08-31 | $1.14M derived: sum of 3 quarters · filed 2026-08-31 | $1.63M 10-K · filed 2026-08-31 |
| 2025-02-28 | $326.00K 10-Q · filed 2026-04-13 | $760.00K derived: sum of 2 quarters · filed 2026-04-13 | $1.25M 10-Q · filed 2026-04-13 | |
| 2024-11-30 | $434.00K 10-Q · filed 2026-01-14 | $927.00K 10-Q · filed 2026-01-14 | ||
| 2024-08-31 | $1.36M 10-Q · filed 2025-10-14 | |||
| 2024-05-31 | $2.34M 10-K · filed 2025-08-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |